Neuroprotective effects of selegiline on rat neural stem cells treated with hydrogen peroxide

Abdanipour,Alireza; Jafari Anarkooli,Iraj; Shokri,Saeed; Ghorbanlou,Mehrdad; Bayati,Vahid; Nejatbakhsh,Reza

doi:10.3892/br.2017.1023

Neuroprotective effects of selegiline on rat neural stem cells treated with hydrogen peroxide

Authors:
- Alireza Abdanipour
- Iraj Jafari Anarkooli
- Saeed Shokri
- Mehrdad Ghorbanlou
- Vahid Bayati
- Reza Nejatbakhsh
View Affiliations

Affiliations: Department of Anatomical Sciences, School of Medicine, Zanjan University of Medical Sciences, Zanjan 45139‑56184, Iran, Cellular and Molecular Research Center, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Khuzestan 6135715794, Iran
Published online on: November 22, 2017 https://doi.org/10.3892/br.2017.1023
Pages: 41-46

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oxidative stress and reactive oxygen species generation have been implicated in the pathogenesis of several neurological disorders including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis and multiple sclerosis. In the present study, the neuroprotective effects of selegiline against hydrogen peroxide‑induced oxidative stress in hippocampus‑derived neural stem cells (NSCs) were evaluated. NSCs isolated from neonatal Wistar rats were pretreated with different doses of selegiline for 48 h and then exposed to 125 µM H2O2 for 30 min. Using MTT and terminal deoxynucleotidyl transferase‑mediated dUTP nick end labeling assays, acridine orange/ethidium bromide staining and reverse transcription‑quantitative polymerase chain reaction, the effects of selegiline on cell survival, apoptosis and the expression of B‑cell lymphoma 2 (Bcl‑2) and heat shock protein 4 (Hspa4) in pretreated stem cells were assessed compared with a control group lacking pretreatment. The results indicated that the viability of cells pretreated with 20 µM selegiline was significantly increased compared with the control group (P<0.05). Additionally, 20 µM selegiline increased the mRNA expression of Bcl‑2 and Hspa4 (P<0.05 vs. control) and suppressed oxidative stress‑induced cell death (apoptosis and necrosis; P<0.05 vs. control and 10 µM groups). From these findings, it was concluded that selegiline may be a therapeutic candidate for the treatment of neurological diseases mediated by oxidative stress.

View Figures

View References

1	DeMaagd G and Philip A: Parkinson's disease and its management: Part 1: Disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. PT. 40:504–532. 2015.
2	Uttara B, Singh AV, Zamboni P and Mahajan RT: Oxidative stress and neurodegenerative diseases: A review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol. 7:65–74. 2009. View Article : Google Scholar : PubMed/NCBI
3	Guo C, Sun L, Chen X and Zhang D: Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regen Res. 8:2003–2014. 2013.PubMed/NCBI
4	Sarkar S, Raymick J and Imam S: Neuroprotective and therapeutic strategies against Parkinson's disease: Recent Perspectives. Int J Mol Sci. 17:172016. View Article : Google Scholar
5	Nayak L and Henchcliffe C: Rasagiline in treatment of Parkinson's disease. Neuropsychiatr Dis Treat. 4:23–32. 2008.PubMed/NCBI
6	Riederer P and Laux G: MAO-inhibitors in Parkinson's disease. Exp Neurobiol. 20:1–17. 2011. View Article : Google Scholar : PubMed/NCBI
7	Bonneh-Barkay D, Ziv N and Finberg JP: Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells. Neuropharmacology. 48:406–416. 2005. View Article : Google Scholar : PubMed/NCBI
8	Lu D, Johnson C, Johnson S, Tazik S and Ou XM: The neuroprotective effect of antidepressant drug via inhibition of TIEG2-MAO B mediated cell death. Drug Discov Ther. 2:289–295. 2008.PubMed/NCBI
9	Zhao Q, Cai D and Bai Y: Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease. Int J Mol Med. 32:883–891. 2013.PubMed/NCBI
10	Hara MR, Thomas B, Cascio MB, Bae BI, Hester LD, Dawson VL, Dawson TM, Sawa A and Snyder SH: Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci USA. 103:pp. 3887–3889. 2006; View Article : Google Scholar : PubMed/NCBI
11	Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB and Naoi M: Neuroprotection by propargylamines in Parkinson's disease: Suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol. 24:675–682. 2002. View Article : Google Scholar : PubMed/NCBI
12	Lecht S, Haroutiunian S, Hoffman A and Lazarovici P: Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy. Ther Clin Risk Manag. 3:467–474. 2007.PubMed/NCBI
13	Fowler JS, Volkow ND, Logan J, Schlyer DJ, MacGregor RR, Wang GJ, Wolf AP, Pappas N, Alexoff D and Shea C: Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: The degree and reversibility of human brain MAO B inhibition by Ro 19 6327. Neurology. 43:1984–1992. 1993. View Article : Google Scholar : PubMed/NCBI
14	Abdanipour A, Tiraihi T and Delshad A: Trans-differentiation of the adipose tissue-derived stem cells into neuron-like cells expressing neurotrophins by selegiline. Iran Biomed J. 15:113–121. 2011.PubMed/NCBI
15	Abdanipour A and Tiraihi T: Induction of adipose-derived stem cell into motoneuron-like cells using selegiline as preinducer. Brain Res. 1440:23–33. 2012. View Article : Google Scholar : PubMed/NCBI
16	Abdanipour A, Sagha M, Noori-Zadeh A, Pakzad I and Tiraihi T: In vitro study of the long-term cortisol treatment effects on the growth rate and proliferation of the neural stem/precursor cells. Neurol Res. 37:117–124. 2015. View Article : Google Scholar : PubMed/NCBI
17	Suzuki S, Namiki J, Shibata S, Mastuzaki Y and Okano H: The neural stem/progenitor cell marker nestin is expressed in proliferative endothelial cells, but not in mature vasculature. J Histochem Cytochem. 58:721–730. 2010. View Article : Google Scholar : PubMed/NCBI
18	Gu J, Chi M, Sun X, Wang G, Li M, Liu L and Li X: Propofol-induced protection of SH-SY5Y cells against hydrogen peroxide is associated with the HO-1 via the ERK pathway. Int J Med Sci. 10:599–606. 2013. View Article : Google Scholar : PubMed/NCBI
19	Han J, Talorete TP, Yamada P and Isoda H: Anti-proliferative and apoptotic effects of oleuropein and hydroxytyrosol on human breast cancer MCF-7 cells. Cytotechnology. 59:45–53. 2009. View Article : Google Scholar : PubMed/NCBI
20	Abdanipour A, Noori-Zadeh A, Mesbah-Namin SA, Bakhtiyari S, Nejatbakhsh R and Anarkooli IJ: Di-(2-ethylhexyl) phthalate-induced hippocampus-derived neural stem cells proliferation. Cell J. 19:166–172. 2017.PubMed/NCBI
21	Didenko VV, Ngo H and Baskin DS: Early necrotic DNA degradation: Presence of blunt-ended DNA breaks, 3′ and 5′ overhangs in apoptosis, but only 5′ overhangs in early necrosis. Am J Pathol. 162:1571–1578. 2003. View Article : Google Scholar : PubMed/NCBI
22	Yuan JS, Reed A, Chen F and Stewart CN Jr: Statistical analysis of real-time PCR data. BMC Bioinformatics. 7:852006. View Article : Google Scholar : PubMed/NCBI
23	Emerit J, Edeas M and Bricaire F: Neurodegenerative diseases and oxidative stress. Biomed Pharmacother. 58:39–46. 2004. View Article : Google Scholar : PubMed/NCBI
24	Ischiropoulos H and Beckman JS: Oxidative stress and nitration in neurodegeneration: Cause, effect, or association? J Clin Invest. 111:163–169. 2003. View Article : Google Scholar : PubMed/NCBI
25	Shih JC, Chen K and Ridd MJ: Monoamine oxidase: From genes to behavior. Annu Rev Neurosci. 22:197–217. 1999. View Article : Google Scholar : PubMed/NCBI
26	Jakubauskiene E, Janaviciute V, Peciuliene I, Söderkvist P and Kanopka A: G/A polymorphism in intronic sequence affects the processing of MAO-B gene in patients with Parkinson disease. FEBS Lett. 586:3698–3704. 2012. View Article : Google Scholar : PubMed/NCBI
27	Youdim MB, Gross A and Finberg JP: Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 132:500–506. 2001. View Article : Google Scholar : PubMed/NCBI
28	Nagatsu T and Sawada M: Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: Possible implications of glial cells. J Neural Transm Suppl. 71:53–65. 2006. View Article : Google Scholar
29	Magyar K and Szende B: (−)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology. 25:233–242. 2004. View Article : Google Scholar : PubMed/NCBI
30	Tsao CM, Jhang JG, Chen SJ, Ka SM, Wu TC, Liaw WJ, Huang HC and Wu CC: Adjuvant potential of selegiline in attenuating organ dysfunction in septic rats with peritonitis. PLoS One. 9:e1084552014. View Article : Google Scholar : PubMed/NCBI
31	Dias V, Junn E and Mouradian MM: The role of oxidative stress in Parkinson's disease. J Parkinsons Dis. 3:461–491. 2013.PubMed/NCBI
32	Chetsawang B, Kooncumchoo P, Govitrapong P and Ebadi M: 1-Methyl-4-phenyl-pyridinium ion-induced oxidative stress, c-Jun phosphorylation and DNA fragmentation factor-45 cleavage in SK-N-SH cells are averted by selegiline. Neurochem Int. 53:283–288. 2008. View Article : Google Scholar : PubMed/NCBI
33	Inaba-Hasegawa K, Akao Y, Maruyama W and Naoi M: Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells. J Neural Transm (Vienna). 120:435–444. 2013. View Article : Google Scholar : PubMed/NCBI
34	Gillies LA and Kuwana T: Apoptosis regulation at the mitochondrial outer membrane. J Cell Biochem. 115:632–640. 2014. View Article : Google Scholar : PubMed/NCBI
35	Shacka JJ and Roth KA: Regulation of neuronal cell death and neurodegeneration by members of the Bcl-2 family: Therapeutic implications. Curr Drug Targets CNS Neurol Disord. 4:25–39. 2005. View Article : Google Scholar : PubMed/NCBI
36	Schwartz PS and Hockenbery DM: Bcl-2-related survival proteins. Cell Death Differ. 13:1250–1255. 2006. View Article : Google Scholar : PubMed/NCBI
37	Shimizu S, Konishi A, Kodama T and Tsujimoto Y: BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. Proc Natl Acad Sci USA. 97:pp. 3100–3105. 2000; View Article : Google Scholar : PubMed/NCBI
38	Malik JM, Shevtsova Z, Bähr M and Kügler S: Long-term in vivo inhibition of CNS neurodegeneration by Bcl-XL gene transfer. Mol Ther. 11:373–381. 2005. View Article : Google Scholar : PubMed/NCBI
39	Offen D, Beart PM, Cheung NS, Pascoe CJ, Hochman A, Gorodin S, Melamed E, Bernard R and Bernard O: Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Proc Natl Acad Sci USA. 95:pp. 5789–5794. 1998; View Article : Google Scholar : PubMed/NCBI
40	Natsume A, Mata M, Goss J, Huang S, Wolfe D, Oligino T, Glorioso J and Fink DJ: Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration. Exp Neurol. 169:231–238. 2001. View Article : Google Scholar : PubMed/NCBI
41	Cao YJ, Shibata T and Rainov NG: Liposome-mediated transfer of the bcl-2 gene results in neuroprotection after in vivo transient focal cerebral ischemia in an animal model. Gene Ther. 9:415–419. 2002. View Article : Google Scholar : PubMed/NCBI
42	Nuydens R, Dispersyn G, Van Den Kieboom G, de Jong M, Connors R, Ramaekers F, Borgers M and Geerts H: Bcl-2 protects neuronal cells against taxol-induced apoptosis by inducing multi-nucleation. Apoptosis. 5:335–343. 2000. View Article : Google Scholar : PubMed/NCBI
43	Nuydens R, Dispersyn G, Van Den Keiboom G, de Jong M, Connors R, Ramaekers F, Borgers M and Geerts H: Bcl-2 protects against apoptosis-related microtubule alterations in neuronal cells. Apoptosis. 5:43–51. 2000. View Article : Google Scholar : PubMed/NCBI
44	Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP and Wang X: Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science. 275:1129–1132. 1997. View Article : Google Scholar : PubMed/NCBI
45	Naoi M, Maruyama W, Akao Y, Yi H and Yamaoka Y: Involvement of type A monoamine oxidase in neurodegeneration: Regulation of mitochondrial signaling leading to cell death or neuroprotection. J Neural Transm Suppl. 71:67–77. 2006. View Article : Google Scholar
46	Naoi M, Maruyama W and Inaba-Hasegawa K: Type A and B monoamine oxidase in age-related neurodegenerative disorders: Their distinct roles in neuronal death and survival. Curr Top Med Chem. 12:2177–2188. 2012. View Article : Google Scholar : PubMed/NCBI
47	Chiou SH, Ku HH, Tsai TH, Lin HL, Chen LH, Chien CS, Ho LL, Lee CH and Chang YL: Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway. Br J Pharmacol. 148:587–598. 2006. View Article : Google Scholar : PubMed/NCBI
48	Jiang B, Liang P, Deng G, Tu Z, Liu M and Xiao X: Increased stability of Bcl-2 in HSP70-mediated protection against apoptosis induced by oxidative stress. Cell Stress Chaperones. 16:143–152. 2011. View Article : Google Scholar : PubMed/NCBI